FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2909773485> ?p ?o ?g. }

• W2909773485 endingPage "683" @default.
• W2909773485 startingPage "673" @default.
• W2909773485 abstract "// Koji Nakamura 1, 2 , Kenjiro Sawada 1 , Mayuko Miyamoto 1 , Yasuto Kinose 1, 3 , Akihiko Yoshimura 1 , Kyoso Ishida 1 , Masaki Kobayashi 1 , Aasa Shimizu 1 , Erika Nakatsuka 1 , Kae Hashimoto 1 , Seiji Mabuchi 1 and Tadashi Kimura 1 1 Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, 5650871, Japan 2 Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA 3 Penn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania Perelman School of Medicine, Biomedical Research Building II/III, Philadelphia, PA, 19104, USA Correspondence to: Kenjiro Sawada, email: daasawada@gyne.med.osaka-u.ac.jp Keywords: microRNA; miR-194-5p; paclitaxel resistance; MDM2; ovarian cancer Received: September 14, 2018      Accepted: January 03, 2019      Published: January 18, 2019 ABSTRACT Paclitaxel is a first-line drug for treating epithelial ovarian cancer (EOC). However, prognosis for patients with advanced stage cancer remains poor due to primary or acquired drug resistance. Therefore, overcoming chemoresistance is one of the greatest challenges in treating EOC. In this study, we identified microRNAs (miRNA) that regulate paclitaxel resistance and tested their potential utility as therapeutic targets. Paclitaxel-resistant cell lines were established using two EOC cell lines: SKVO3ip1 and HeyA8. miRNA PCR arrays showed that miR-194-5p was downregulated in paclitaxel-resistant cells. Forced expression of miR-194-5p resensitized resistant cells to paclitaxel. Conversely, miR-194-5p inhibition induced paclitaxel resistance in parental cells. In silico analysis and luciferase reporter assay revealed that MDM2 is a direct target of miR-194-5p. MDM2 was upregulated in paclitaxel resistant cells compared with parental cells. MDM2 inhibition also resensitized resistant cells to paclitaxel and forced MDM2 induced paclitaxel resistance in parental cells. miR-194-5p induced p21 upregulation and G1 phase arrest in resistant cells by downregulating MDM2 . Furthermore, a public database showed that high MDM2 expression was associated with a shorter progression-free survival in EOC patients treated with paclitaxel. Collectively, our results show that restoring miR-194-5p expression resensitizes EOCs to paclitaxel, and this may be exploited as a therapeutic option." @default.
• W2909773485 created "2019-01-25" @default.
• W2909773485 creator A5006897018 @default.
• W2909773485 creator A5008483463 @default.
• W2909773485 creator A5008987026 @default.
• W2909773485 creator A5021245467 @default.
• W2909773485 creator A5031427780 @default.
• W2909773485 creator A5032402076 @default.
• W2909773485 creator A5055405608 @default.
• W2909773485 creator A5061219676 @default.
• W2909773485 creator A5069577547 @default.
• W2909773485 creator A5081766370 @default.
• W2909773485 creator A5085657160 @default.
• W2909773485 creator A5090684583 @default.
• W2909773485 date "2019-01-18" @default.
• W2909773485 modified "2023-10-15" @default.
• W2909773485 title "Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression" @default.
• W2909773485 cites W1549261396 @default.
• W2909773485 cites W1574056173 @default.
• W2909773485 cites W1623600373 @default.
• W2909773485 cites W1751321717 @default.
• W2909773485 cites W1914632472 @default.
• W2909773485 cites W1965531638 @default.
• W2909773485 cites W1991451193 @default.
• W2909773485 cites W1994637651 @default.
• W2909773485 cites W1997338647 @default.
• W2909773485 cites W1998258610 @default.
• W2909773485 cites W2003684914 @default.
• W2909773485 cites W2016046687 @default.
• W2909773485 cites W2022796941 @default.
• W2909773485 cites W2023486531 @default.
• W2909773485 cites W2096076701 @default.
• W2909773485 cites W2097105130 @default.
• W2909773485 cites W2109227959 @default.
• W2909773485 cites W2114570899 @default.
• W2909773485 cites W2119312052 @default.
• W2909773485 cites W2125713917 @default.
• W2909773485 cites W2134629862 @default.
• W2909773485 cites W2143017330 @default.
• W2909773485 cites W2157666410 @default.
• W2909773485 cites W2162527129 @default.
• W2909773485 cites W2167978831 @default.
• W2909773485 cites W2171398108 @default.
• W2909773485 cites W2328421677 @default.
• W2909773485 cites W2346330623 @default.
• W2909773485 cites W2410161518 @default.
• W2909773485 cites W2509512733 @default.
• W2909773485 cites W2570618306 @default.
• W2909773485 cites W2751143162 @default.
• W2909773485 cites W2767653597 @default.
• W2909773485 cites W2792995236 @default.
• W2909773485 cites W4318220576 @default.
• W2909773485 doi "https://doi.org/10.18632/oncotarget.26586" @default.
• W2909773485 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6363016" @default.
• W2909773485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30774764" @default.
• W2909773485 hasPublicationYear "2019" @default.
• W2909773485 type Work @default.
• W2909773485 sameAs 2909773485 @default.
• W2909773485 citedByCount "27" @default.
• W2909773485 countsByYear W29097734852019 @default.
• W2909773485 countsByYear W29097734852020 @default.
• W2909773485 countsByYear W29097734852021 @default.
• W2909773485 countsByYear W29097734852022 @default.
• W2909773485 countsByYear W29097734852023 @default.
• W2909773485 crossrefType "journal-article" @default.
• W2909773485 hasAuthorship W2909773485A5006897018 @default.
• W2909773485 hasAuthorship W2909773485A5008483463 @default.
• W2909773485 hasAuthorship W2909773485A5008987026 @default.
• W2909773485 hasAuthorship W2909773485A5021245467 @default.
• W2909773485 hasAuthorship W2909773485A5031427780 @default.
• W2909773485 hasAuthorship W2909773485A5032402076 @default.
• W2909773485 hasAuthorship W2909773485A5055405608 @default.
• W2909773485 hasAuthorship W2909773485A5061219676 @default.
• W2909773485 hasAuthorship W2909773485A5069577547 @default.
• W2909773485 hasAuthorship W2909773485A5081766370 @default.
• W2909773485 hasAuthorship W2909773485A5085657160 @default.
• W2909773485 hasAuthorship W2909773485A5090684583 @default.
• W2909773485 hasBestOaLocation W29097734851 @default.
• W2909773485 hasConcept C104317684 @default.
• W2909773485 hasConcept C114851261 @default.
• W2909773485 hasConcept C121608353 @default.
• W2909773485 hasConcept C126322002 @default.
• W2909773485 hasConcept C127561419 @default.
• W2909773485 hasConcept C143998085 @default.
• W2909773485 hasConcept C145059251 @default.
• W2909773485 hasConcept C2777292972 @default.
• W2909773485 hasConcept C2780427987 @default.
• W2909773485 hasConcept C502942594 @default.
• W2909773485 hasConcept C54355233 @default.
• W2909773485 hasConcept C71924100 @default.
• W2909773485 hasConcept C86803240 @default.
• W2909773485 hasConceptScore W2909773485C104317684 @default.
• W2909773485 hasConceptScore W2909773485C114851261 @default.
• W2909773485 hasConceptScore W2909773485C121608353 @default.
• W2909773485 hasConceptScore W2909773485C126322002 @default.
• W2909773485 hasConceptScore W2909773485C127561419 @default.
• W2909773485 hasConceptScore W2909773485C143998085 @default.
• W2909773485 hasConceptScore W2909773485C145059251 @default.

• next